-
Clin Gastroenterology H: Using proton pump inhibitors increases the risk of kidney stones
Time of Update: 2021-01-15
use of antihistamine drugs (H2RAs) was also associated with an increased risk of kidney stones (corrected HR, 1.47; CI 1.31-1.64).
-
The combined chemotherapy of SABCS-Mershaton K drug treated with three-yin breast cancer was better than that of Roche's T-drug combination
Time of Update: 2021-01-15
reduced the risk of disease development or death by 67 percent in previously untreated metastasis triple-negative breast cancer patients, who had a combined positive score (CPS) of at least 10 for PD-L1, a biomarker of tumor expression
-
Clin Gastroenterology H: Peak concentrations of Usnu monoantigen resistance were associated
Time of Update: 2021-01-15
the relationship between the serum concentration of usthabyn resistance during the two-week treatment and endoscopic and bio-chemical remission in patients with CD. In this forward-looking observational study, due to endoscopic markers of active CDs
-
Clin Gastroenterology H: "Useless" or "no way" - patients with irritable bowel syndrome are willing
Time of Update: 2021-01-15
IBS patients are willing to pay an average of $73 a month (if they earn $75,000 a year) and $197 (if they earn $75,000 a year) for pain medications.
-
Beda Pharmaceuticals intends to issue H shares and apply for listing on the main board of the Hong Kong Stock Exchange
Time of Update: 2021-01-15
On January 7, Beda Pharmaceuticals announced that its board of directors had considered and approved the company's issuance of foreign-listed foreign shares (H-shares) and applied for listing on the main board of the Stock Exchange of Hong Kong
-
China NMPA receives the NDA of Envafolimab (KN035) for the treatment of MSI-H/dMMR advanced solid tumors
Time of Update: 2021-01-15
Biopharmaceutical company TRACON announced today that China's State Drug Administration (NMPA) has accepted a new drug application (NDA) from Envafolimab (KN035) for the treatment of MSI-H/dMMR advanced solid tumors.
-
Clin Gastroenterology H: Reducing the duration of use of Usnu monoantigen can improve the effectiveness of treatment for Crohn's disease
Time of Update: 2021-01-15
the study, researchers confirmed that reducing the interval between usanu monoantigens to four weeks for non-responsive CD patients at 90 mg per 8 weeks could improve clinical and biological indicators of disease activity.
-
Clin Gastroenterology H: A healthy lifestyle is associated with a decrease in mortality in patients with inflammatory bowel disease
Time of Update: 2021-01-15
A healthy lifestyle not only gives us a strong body, but also relieves the malignant effects of certain diseases. is unclear whether a healthy lifestyle affects mortality in patients with inflammatory bowel disease (IBD), including Crohn's
-
T-cell therapy combination K drug in PD-L1 positive r/r DLBCL patients ORR up to 86%!
Time of Update: 2021-01-10
IMV is a clinical phase biopharmaceutical company dedicated to innovative immunotherapy. recently, the company announced that its new T-cell therapy DPX-Survivac combined with Mercadon anti-PD-1 therapy Keytruda (Corida, generic name
-
K drug approved for treatment of triple negative breast cancer in combination with chemotherapy to reduce the risk of disease progression by 35%
Time of Update: 2021-01-10
Retrieved November 13, 2020, from [2] Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC).
-
MSI-H/dMMR Advanced Solid Tumors: How do each PD-1/PD-L1 perform?
Time of Update: 2021-01-09
, multi-parallel control, open-label Phase II clinical study CheckMate-142, a total of 74 patients received O-drug treatment (3mg/kg, intravenous injection, every two weeks), the main endpoint of the study is ORR. the results of the single-drug
-
CD30/CD16A dual-specific teteal antibody combination K drug therapy R/R HL is better than single drug therapy
Time of Update: 2021-01-08
of Keytruda single-drug therapy in similar patient groups: in the KEYNOTE-087 study, Keytruda single-drug treatment had ORR of 69% and CR of 22.4%. the study, AFM13 and Keytruda were well-to-do and had similar safety requirements to those known
-
Coss's innovative steering wheel cover debuted at the K exhibition
Time of Update: 2021-01-08
Recently, chemical giant Covestro opened the design prototype of a new steering wheel sleeve at the International Plastics and Rubber Show ("K Exhibition") in Dusseldorf, Germany, using a new direct coating process.
-
Under-skin injection PD-L1 single anti-KN035 listing application was accepted by CDE! Treatment of MSI-H/dMMR solid tumors
Time of Update: 2021-01-04
On December 22, Corning Jerry Biopharmaceuticals ("Corning Jerry") announced that it had reached a strategic partnership with Syndicate Pharmaceuticals Group Co., Ltd. ("First Sound Pharmaceuticals") to restructure the humanized PD-L1 mono-domain
-
The combination therapy of Q-K treats NSCLC I/II clinical effects is encouraging and phase III clinical practice is planned
Time of Update: 2021-01-01
TRAEs of level 3 and above. addition, OrR was 40.0% (95%CI, 24.9-56.7) and 37.5% (95% CI, 22.7-) in NSCLC patients. 54.2), 27.5 per cent (95 per cent CI, 14.6-43.9) and 35.7 per cent (95 per cent CI, 12.8-64.9). the results showed that the Q
-
"Pharmaceutical Express" K drug combination therapy by the FDA priority review of Bedane Shatini...
Time of Update: 2020-12-30
variety; Beda Pharmaceuticals Ensarini is priced out; and it is reported that the company is going to lay off workers again... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief The Health Insurance Bureau
-
The treatment of MSI-H-dMMR metastatic colorectal cancer with Mercedon K drug is recommended by CHMP in the European Union
Time of Update: 2020-12-27
as a single-drug treatment for adult patients with microsatellite highly unstable (MSI-H) or mismatched repair defective type (dMMR) colorectal cancer. recommendation is based on the results of the key Phase III clinical KEYNOTE-177 (NCT02563002
-
Colorectal Cancer (CRC) Precision Medicine! Mercadon Keytruda is recommended by THECHMP for approval: first-line treatment MSI-H/dMMR metastasis CRC!
Time of Update: 2020-12-27
-Dess-High Advanced Colorectal Cancer. colorectal cancer (Photo: medicalnewstoday.com) Colorectal cancer (CRC) is a cancer that is found in the colon or rectum, which is part of the body's digestive or gastrointestinal system. CRC
-
K drug combined with LENVIMA treatment of advanced endometrial cancer III. Phase III clinical reached a double main endpoint
Time of Update: 2020-12-23
generally face high mortality rates and limited treatment options, and the results of the Phase III trial of the joint programme also give patients new hope and hope. collaboration with Mercadon began in March 2018 with the global joint development
-
2 years later it's still remission! "K medicine" is expected to be the first line of treatment for metastatic colorectal cancer
Time of Update: 2020-12-22
in the body, specializing in DNA bug fixing. these genes mutate, errors in DNA replication cannot be repaired in time, and cancer cells are more likely to cause cancerous mutations. about 5% of patients with metastatic colorectal cancer
